|
|
News Breaks
|
February 14, 2012
|
| 00:02 EDT |  | REGN |
| theflyonthewall.com: | Regeneron’s Eylea sales need to rise to boost the stock further, Barron's says | | Trading at more than 20x sales, Regeneron (REGN) is no bargain. For Regeneron's stock price to keep moving higher, Eylea sales will likely have to keep beating expectations. Also the company will likely have to deliver a steady stream of good news regarding drug candidates in its pipeline, Barron's says. Regeneron isn't expected to turn a profit until 2014. Reference Link :theflyonthewall.com |
|
|
News For REGN From The Last 14 Days Check below for free stories on REGN the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
